01—Abstract
Summary
Summary of the 8-K filed May 27, 2026. Cited figures are marked; the original filing is the authoritative source.
Labcorp Holdings Inc. (NYSE: LH) furnished a Current Report on Form 8-K under Item 7.01 (Regulation FD Disclosure) on May 27, 2026, announcing that it will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, from 12:15 pm to 12:45 pm ET.
The presentation will be available via live webcast on the Labcorp Investor Relations website at ir.labcorp.com. The filing is informational in nature and contains no financial results, guidance, or other quantitative financial data. An archived recording of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days following the event.
The accompanying press release (Exhibit 99.1) is incorporated by reference and furnished under this Item. The press release also describes Labcorp as a global laboratory services company with nearly 71,000 employees serving clients in approximately 100 countries, supporting more than 85%a of new drugs and therapeutic products approved by the FDA in 2025, and performing more than 750 million tests for patients worldwide. For investors, the filing is primarily a scheduling notice for management's conference appearance rather than a source of new financial information.
02—Key points
Key Highlights
- Labcorp will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, from 12:15 pm to 12:45 pm ET.
- The presentation will be accessible via live webcast on the Labcorp Investor Relations website (ir.labcorp.com).
- An archived recording will be available approximately 24 hours after the session ends and accessible for 90 days after the event.
- The filing is furnished under Item 7.01 (Regulation FD Disclosure), and the press release is furnished as Exhibit 99.1.
- The filing contains no financial results, earnings figures, or guidance.
- The company cites support for more than 85% of new drugs and therapeutic products approved by the FDA in 2025.
- Labcorp reports nearly 71,000 employees, serving clients in approximately 100 countries and performing more than 750 million tests.
03—Questions
Frequently Asked Questions
What is the purpose of this 8-K filing?
The filing furnishes a press release under Item 7.01 (Regulation FD Disclosure) announcing that Labcorp will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026.
When and how can investors access the presentation?
The presentation takes place Wednesday, June 3, from 12:15 pm to 12:45 pm ET and can be viewed via live webcast on the Labcorp Investor Relations website at ir.labcorp.com.
Will a recording of the presentation be available?
Yes. An archived, recorded version will be available approximately 24 hours after the session ends and can be accessed for 90 days following the event.
Does this filing include financial results or guidance?
No. The filing is an event notice regarding a conference presentation and does not contain financial results, earnings, or guidance.
Who are the investor relations contacts named in the press release?
The press release lists Dewey Steadman as the investor contact, reachable at [email protected], and Racquel White as the media contact, reachable at [email protected].
04—Continue